(Q41979947)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Howard Gurney

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

10

Toni K Choueiri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

16

Cora N Sternberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Nicholas J. Vogelzang

7

object named as

Nicholas J Vogelzang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Joaquim Bellmunt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Ronald de Wit

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

David J Vaughn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Yves Fradet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Jae-Lyun Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Lawrence Fong

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Miguel A Climent

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Daniel P Petrylak

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Winald Gerritsen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

David I Quinn

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Stéphane Culine

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Yabing Mai

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Christian H Poehlein

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Rodolfo F Perini

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Dean F Bajorin

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

KEYNOTE-045 Investigators

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

language of work or name

English

0 references

publication date

17 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

The New England Journal of Medicine

3 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

1015-1026

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

3 April 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Gene-expression profiling to predict responsiveness to immunotherapy

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Molecular biology and targeted therapies for urothelial carcinoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Global cancer statistics, 2012

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5635424

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy

18 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28212060

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1613683

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28212060%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PubMed publication ID

28212060

1 reference